Browse the evidence

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Tirzepatide use is associated with a significantly higher incidence of gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, compared to placebo, although serious adverse event rates remain comparable.

Expect gastrointestinal side effects when starting tirzepatide. Nausea, vomiting, and diarrhea are significantly more common than with a placebo, particularly when starting or increasing the dose. However, these are typically mild to moderate and do not appear to increase the risk of serious health events. Most patients tolerate the medication well enough to continue treatment, which is necessary to achieve the significant weight loss benefits.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, constipation, dyspepsia) compared to placebo, which increases with dose and leads to higher discontinuation rates, but does not increase the risk of serious adverse events.

Tirzepatide is more likely to cause stomach issues like nausea and vomiting than a placebo, and these side effects are more common at higher doses. This can lead to some people stopping the medication, but it does not increase the risk of serious health problems. Managing these side effects is key to staying on the treatment.

Tirzepatide use is associated with a significantly higher incidence of adverse reactions, particularly nausea and diarrhea, which are dose-dependent and increase with higher doses (15mg).

Be prepared for potential side effects like nausea and diarrhea when starting Tirzepatide. These side effects are more likely at higher doses (15mg) and may decrease over time as your body adjusts. Most people tolerate the medication well, but it's important to discuss these potential side effects with your doctor.

Tirzepatide use is associated with a significantly increased incidence of adverse reactions, particularly gastrointestinal issues like nausea and diarrhea, which are dose-dependent.

Be prepared for potential side effects when starting Tirzepatide. Nausea and diarrhea are common, especially when you first start or increase the dose. These symptoms often improve over time. Starting at a lower dose (2.5mg) and gradually increasing can help your body adjust. Most people find the side effects manageable.

GIP is the predominant incretin hormone in humans responsible for the majority of the incretin effect on postprandial insulin secretion, although its insulinotropic action is impaired in type 2 diabetes due to receptor downregulation.

Your body naturally produces GIP, which is the main hormone helping your pancreas release insulin after eating. In type 2 diabetes, this GIP signal gets weaker because the receptors on your insulin-producing cells become less sensitive. This is why treatments that target both GIP and GLP-1 receptors are often more effective than targeting GLP-1 alone.

In type 2 diabetes, the insulinotropic effect of GIP is significantly reduced or absent, primarily due to hyperglycemia-induced downregulation and degradation of the GIP receptor (GIPR) on beta cells.

In type 2 diabetes, your body still makes GIP, but your insulin cells stop listening to it because high blood sugar damages the receptors. This is reversible: lowering your blood sugar with medication or lifestyle changes can restore your body's natural ability to respond to GIP.

Using assumed or estimated menstrual cycle phases (e.g., calendar-based counting) instead of direct biochemical verification (e.g., LH surge, progesterone levels) produces invalid and unreliable data in sport-related research.

Do not use calendar-based methods or apps to assign menstrual cycle phases in research or applied practice without biochemical verification. To accurately determine phases (e.g., follicular vs. luteal), you must measure biological markers such as urinary luteinizing hormone (LH) surges and serum/saliva progesterone levels. Relying on calendar counting alone is scientifically invalid due to high inter- and intra-individual variability in ovulation timing and the prevalence of subtle menstrual disturbances.

Elevated plasma levels of endotrophin, the C-terminal cleavage product of collagen type VI alpha 3 (COL6A3), causally increase the risk of coronary artery disease, acting as a primary mediator linking obesity to cardiometabolic disease.

Obesity increases the risk of heart disease partly by raising levels of a specific protein fragment called endotrophin. This fragment is created when body fat increases, specifically from abdominal subcutaneous fat. The good news is that losing body fat reduces these levels. Therefore, weight loss interventions that reduce abdominal adiposity are likely to lower this specific biological risk factor for coronary artery disease.

Metabolic bariatric surgery (MBS) is the most effective intervention for achieving long-term and sustained weight loss and can reverse certain metabolic defects like insulin resistance by altering gut hormone secretion.

For severe obesity, lifestyle changes alone are often insufficient. Metabolic bariatric surgery (like gastric bypass) is currently the most effective treatment for long-term weight loss and can reverse metabolic issues like diabetes by changing gut hormones.

Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.

Stop blaming yourself for your weight. Obesity is a biological disease involving hormones and brain signaling, not a character flaw. Seek medical care that treats the underlying biology, not just willpower.

Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.

Maintaining a healthy weight reduces your risk of several cancers. Focus on sustainable lifestyle changes to lower your risk.

GLP-1 receptor agonists significantly increase the volume of retained gastric contents in fasting patients, but this does not translate to a statistically significant increase in actual pulmonary aspiration rates.

If you take a GLP-1 drug (like Ozempic or Wegovy) and have surgery, your stomach might stay fuller longer, but you are not significantly more likely to vomit into your lungs than someone who doesn't take it. Do not stop your medication without asking your surgeon or anesthesiologist, as modern guidelines suggest continuing it for most people while using other safety checks like ultrasound.

Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.

GIP naturally helps your body release insulin after eating. Early treatments tried adding more GIP, but it didn't work well in diabetics. New research shows that blocking GIP's natural signal helps scientists understand its true role, which is still to boost insulin, even in diabetes.

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.

Understand that obesity is a complex biological condition influenced by genetics and environment, not a simple failure of willpower. This perspective shifts the focus from self-blame to seeking effective, biologically-targeted treatments and lifestyle adjustments that work with your body's natural regulatory systems.

GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.

GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.

SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.

If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.

Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.

Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.

Obesity is a chronic, highly heritable neurological disease driven by central nervous system regulation of satiety and reward, rather than solely a behavioral failure of willpower.

Obesity is a biological condition involving brain pathways that control hunger and reward, heavily influenced by genetics. This means it is not simply a failure of willpower. Effective management often requires addressing these biological drivers, potentially through medical therapies that target these specific pathways, rather than relying solely on lifestyle changes which may be insufficient for those with high genetic risk.

GLP-1 receptor agonists provide significant cardiovascular risk reduction in both diabetic and non-diabetic patients with established cardiovascular disease, a benefit that is significantly under-recognized by physicians, particularly for non-diabetic patients.

For patients with obesity and established cardiovascular disease, GLP-1 agonists offer significant cardiovascular risk reduction (20% reduction in MACE in non-diabetics). Prescribers should be aware of these benefits to ensure appropriate patient selection and counseling, regardless of diabetic status.